Important. Please Read Before Completing This Risk Profile Form.

重要讯息. 填写本风险侧写表前请仔细阅读.

互联网

The first group's risk profile is no worse than diabetics ', according to AllLife.

据AllLife称, 前者的风险系数与糖尿病患者几乎无异.

互联网

Methods : To review the benefit : risk profile of Gefitinib and Erlotinib in Asian patients with advanced NSCLC.

目的回顾性分析亚裔晚期NSCLC患者使用 吉非 替尼的临床研究,了解亚裔患者使用吉非替尼后的疗效与毒性反应.

互联网